Every 8-K that Evofem Bioscienc (EVFM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow EVFM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVFM filings page.
Evofem Biosciences, Inc. reports that it periodically presents and distributes slide presentations to the investment community to provide updates and summaries of its business. A copy of its current corporate slide presentation, prepared as of July 20, 2026, is being made available on the Investors section of its website.
The same corporate slide deck is furnished as Exhibit 99.1 to a report dated July 20, 2026, together with a Cover Page Interactive Data File as Exhibit 104. The company states that the information in Item 7.01, including Exhibit 99.1, is being furnished and not deemed filed under the Securities Exchange Act of 1934, and is not incorporated by reference into Securities Act or Exchange Act filings unless specifically referenced. The report is signed on behalf of the company by Chief Executive Officer Saundra Pelletier.
Evofem Biosciences, Inc. incurred new subordinated debt by issuing a promissory note to HUB Cyber Security, Ltd. with an aggregate original principal amount of $706,304. The note bears interest at 12% per annum, compounded monthly, and matures eleven months after July 8, 2026, unless due earlier under its terms.
The note also carries a $2,000 per week Monitoring Fee starting on issuance (approximately $94,000 if outstanding through maturity) and a one-time $14,126 Administration Fee, both payable at maturity. It may be prepaid at any time without premium or penalty, and is a subordinated obligation. Covenants restrict mergers, major asset sales, liquidation, material changes to the business, and certain shareholder payments, and require notice of judgments and events of default. Standard default triggers apply, while defaults alleged by the company’s senior noteholder are expressly excluded as events of default under this note.
Evofem Biosciences, Inc. reported first quarter 2026 results, showing small revenue growth but a return to loss. Net sales were $0.9 million for the three months ended March 31, 2026, slightly above $0.8 million a year earlier, driven by higher pricing and a better gross-to-net mix for PHEXX and SOLOSEC.
Total operating expenses were $5.5 million, leading to a net loss of $5.5 million, or $(0.04) per share, compared with net income attributable to common stockholders of $1.0 million, or $0.01 per basic share, in the prior-year quarter. The balance sheet shows cash and cash equivalents of $1.5 million and a stockholders’ deficit of $77.6 million, highlighting ongoing financial strain.
The company is pursuing growth by commercializing its FDA-approved products PHEXX and SOLOSEC outside the U.S., including a new distribution agreement for SOLOSEC in Sub-Saharan Africa and ongoing regulatory review for both products in the United Arab Emirates. Management reiterates forward-looking statements that emphasize plans for cost reductions, manufacturing efficiencies, and ex-U.S. expansion, while warning about limited cash resources, dependence on new capital or business development transactions, and its ability to continue as a going concern.
Evofem Biosciences has signed a five-year exclusive distributorship agreement with Clovis Davis Pharmaceuticals to commercialize SOLOSEC (secnidazole) 2 g oral granules in sub-Saharan Africa. Clovis Davis will handle distribution, promotion, marketing, and sales across the Territory.
Local regulatory filings will rely on Evofem’s existing U.S. FDA registration dossier for SOLOSEC, an approved single-dose oral antibiotic for bacterial vaginosis and trichomoniasis. The company highlights significant unmet need, noting that bacterial vaginosis is estimated to affect 25% of women in sub-Saharan Africa, and that in Ethiopia an estimated 10.9 million women may be eligible for SOLOSEC treatment.
Evofem Biosciences, Inc. entered into a fourth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund entities covering previously issued convertible promissory notes. The amendment sets the notes’ maturity as the earlier of six months after April 10, 2026, an Adjuvant‑elected change of control, or any contractual acceleration, and restricts prepayment before six months without Adjuvant’s written consent.
Evofem Biosciences, Inc. reports that it has mutually terminated its License and Supply Agreement with Windtree Therapeutics, Inc., which had made Windtree a manufacturer and supplier of PHEXXI® (lactic acid, citric acid, and potassium bitartrate). The parties entered into a Termination Agreement effective March 13, 2026.
The company states that there are no termination or other fees payable in connection with ending this agreement, helping avoid an immediate financial charge from this change. Certain customary provisions of the original agreement that are meant to survive termination will remain in effect.
Evofem Biosciences reported its fifth consecutive year of net sales growth and a return to profitability for 2025. Full-year net sales were $20.2 million, up from $19.4 million, as higher PHEXX WAC, a better gross-to-net ratio, and a full year of SOLOSEC sales supported growth.
Total operating expenses fell to $16.8 million, a $10.2 million reduction, driving operating income of $3.4 million versus a $7.7 million loss in 2024. Net income attributable to common stockholders was $0.3 million, or $0.00 per basic and diluted share, compared with a $9.0 million net loss, or ($0.11) per share.
In the fourth quarter of 2025, net sales rose to $9.6 million from $7.1 million, a 35% increase, with operating income improving to $3.3 million from a $1.0 million loss. Quarterly net income reached $2.8 million, or $0.02 per basic share and $0.00 per diluted share, versus a $3.0 million net loss a year earlier.
Evofem Biosciences, Inc. reported that it has posted its current corporate slide presentation to the Investors section of its website. The same presentation is being used at various industry and investor conferences to provide updates and summaries of the company’s business.
The slide deck is included as Exhibit 99.1 to this report and is described as having been prepared as of January 12, 2026. Evofem states that it has no obligation to update, supplement, or amend these materials and clarifies that the information in the exhibit is being furnished, not filed, so it is not automatically subject to certain Exchange Act liabilities or incorporation by reference into other securities law documents.
Evofem Biosciences, Inc. reported results of its November 26, 2025 Annual Meeting of Stockholders. Stockholders approved an amendment to the Certificate of Incorporation authorizing a one-time reverse stock split of the outstanding Common Stock at a ratio of not less than 1-for-500 and not more than 1-for-1,500, with the exact ratio to be set by the Board any time before November 26, 2026. The total authorized Common Stock remains unchanged.
Stockholders also elected four directors to serve until the 2028 annual meeting, approved on a non-binding basis the compensation of named executive officers, and approved the Evofem Biosciences, Inc. 2025 Equity Incentive Plan. They further ratified the appointment of BPM LLP as independent registered public accounting firm for the year ending December 31, 2025.
Evofem Biosciences (EVFM) furnished earnings information via an Item 2.02 Form 8-K. The company announced it issued a press release with financial results for the three and nine months ended September 30, 2025, attached as Exhibit 99.1.
The disclosure is furnished, not filed, and is not incorporated by reference unless expressly stated. The company’s forward-looking statements address topics such as COGS reduction initiatives, future sales trends, cost-reduction efforts, manufacturing efficiencies, international expansion, and its ability to obtain additional financing or other strategic alternatives, and are subject to risks including limited cash resources, reliance on new capital, potential regulatory delays, market demand changes, supply chain factors, and the nonrecurring nature of certain gains.
Evofem Biosciences (EVFM) terminated its merger agreement with Aditxt effective October 20, 2025, after stockholders did not approve the transaction. The company exercised its contractual right to terminate based on the merger’s outside date and the failure to obtain Company Shareholder Approval. All related ancillary agreements ended concurrently, except for the existing non‑disclosure agreement. No consideration was paid in connection with the termination.
At the October 20 special meeting, quorum was reached with 100,494,436 votes represented out of 256,360,511 eligible votes. Proposal 1 to approve the merger received 93,239,872 votes for, 7,208,466 against, and 46,097 withheld, and was not approved. Proposal 2, authorizing potential adjournment, passed with 97,435,999 for, 2,840,322 against, and 218,115 withheld.
The company cautioned that termination could affect operations and relationships and referenced risks including potential costs and obligations described in its risk disclosures.
Evofem Biosciences (EVFM) entered a third amendment to its Securities Purchase Agreement with Adjuvant on October 13, 2025. The amendment updates when the related convertible notes become payable in full to the earlier of six months after the Effective Date, at Adjuvant’s election upon a Change of Control, or the date of any acceleration under Section 8.
The notes may not be prepaid before the date that is six months after the Effective Date without Adjuvant’s prior written consent. This sets a defined near‑term timeline for potential repayment while limiting early prepayment.